Overactive Bladder (178-MA-1005)

Overactive Bladder (OAB) is a frequent condition affecting older adults and the urinary frequency and urgency associated with the condition are often highly debilitating. In addition, OAB related urinary incontinence has been associated with other health related problems in seniors including falls, fractures, urinary tract infections (UTIs), skin infections, depression, and chronic constipation.

The purpose of the study is to see if a drug called mirabegron (MYRBETRIQ®) is both effective and safe as a treatment for OAB in older adults as compared to placebo. The placebo is a tablet that looks like a drug but has no drug in it. Mirabegron is a Health Canada approved product. Everyone in the study will receive placebo during the first 2 weeks. Some subjects will receive it during the entire study.

Register Today!

Trial Information

StatusIn Recruitment
Start DateNovember 2016
End DateApril 2017
Trial Duration20 weeks
Number of Visits6
Lead CRCAdam Pawluch

For additional information
on this trial contact: